Lexie B3 vs Resound Vivia 9 60S microRIE

The Lexie B3 is a mid-priced OTC hearing aid available at $999 that achieves an A grade with a SoundScore of 4.7/5 in our lab testing, ranking #1 among 65 OTC hearing aid devices tested. This behind-the-ear style device delivers category-leading performance across multiple metrics. Speech clarity is a standout strength. In our lab testing, the Lexie B3 scores an excellent 4.5/5 for speech in quiet, measuring 1.73 points above the OTC category average. Speech in noise performance scores 2.5/5—above the category average by 1.02 points, though only mixed in absolute terms at 2.5/5. This pattern reflects the broader challenge OTC devices face in noisy environments while still positioning the B3 as a top performer relative to its category. Music streaming quality is solid at 3.3/5, outperforming the category average by 1.38 points. Own-voice comfort scores a solid 3.0/5, sitting 0.49 points above average. Feedback handling is excellent at 4.6/5, essentially matching the already-strong category average. The Lexie B3 is best suited for consumers seeking top-tier OTC sound performance without prescription hearing aid costs. Those who prioritize speech clarity in quieter settings will find particular value here. Budget-conscious shoppers may want to consider alternatives like the RxEars Rxi, which offers strong performance at a lower price point.

The ReSound Vivia 9 60S microRIE is a premium prescription behind-the-ear hearing aid released in 2025, currently available at $3,798. In our lab testing, it earned a B grade with a SoundScore of 3.9/5, ranking #29 of 39 prescription hearing aids tested. This device shows a mixed performance profile. Its standout strength is own-voice comfort, scoring 3.4/5—a solid result that sits 0.70 points above the category average. Speech clarity in quiet environments also performs at category average with a score of 3.4/5. Feedback handling is strong in absolute terms at 4.2/5, though this falls 0.52 points below the category average, reflecting the high bar set by competing prescription devices. The Vivia 9's most notable weakness is speech understanding in noisy environments, where it scored just 1.1/5—a low result that trails the category average by 0.96 points. Music streaming performance is mixed at 2.6/5, sitting slightly below average. These limitations are worth considering given the premium price positioning. For listeners who prioritize comfortable own-voice perception and primarily encounter quieter listening situations, the Vivia 9 may be suitable. However, those frequently in challenging noise environments should note that several alternatives in this price range—including the Phonak Sphere Infinio and Oticon Intent—deliver stronger overall performance in our testing. Budget-conscious shoppers may also find comparable sound quality at lower price points with options like the Jabra Enhance Pro 20 at Costco.